The future of the global subcutaneous drug delivery device market looks promising with opportunities in the hospital pharmacies, retail pharmacies and online pharmacies markets.
- Within the product category, prefilled syringes will remain the largest segment over the forecast period as the increasing demand for convenient drug administration.
- Within the distribution channel category, hospital pharmacies will remain the largest segment due to the growing need for specialized medication administration.
- In terms of regions, North America will remain the largest region over the forecast period due to the increasing demand for self-administered drug delivery devices.
Emerging Trends in Subcutaneous Drug Delivery Device Market
The subcutaneous drug delivery device market is evolving through advances in wearable injectors, prefilled syringes, and autoinjectors. Growing biologic pipelines and demand for home based treatment are encouraging pharmaceutical partnerships. Lucintel monitors these developments as manufacturers pursue more convenient, scalable delivery solutions during 2025 and 2026.- Wearable Injector Adoption: Pharmaceutical companies are advancing wearable devices for biologics requiring larger injection volumes. In July 2025, BD reported clinical evaluation of its Libertas platform, designed for formulations up to 10 milliliters; Enable Injections received European regulatory approval for enFuse in March 2025. These developments support convenient administration and could expand wearable injector adoption over the next three to five years.
- Large Volume Drug Delivery: Device manufacturers are developing systems capable of delivering larger doses subcutaneously. In October 2025, SCHOTT Pharma introduced a commercially available 5.5 milliliter prefillable glass syringe compatible with Ypsomed's large volume autoinjector. BD also advanced wearable configurations supporting volumes up to 10 milliliters. These innovations could help pharmaceutical companies shift suitable biologic therapies away from intravenous administration.
- Expansion of Prefilled Autoinjectors: Pharmaceutical companies are increasingly offering ready to use injection formats. In December 2025, the US Food and Drug Administration recorded approval of GSK's Exdensur in autoinjector and prefilled syringe presentations. In January 2025, the agency approved Celltrion's Avtozma in both formats. Such launches could strengthen demand for integrated delivery devices and improve treatment convenience.
- International Regulatory Expansion: Manufacturers are pursuing additional markets for wearable delivery platforms. Enable Injections announced Brazilian regulatory approval for enFuse in August 2025, following European approval in March. These milestones widen potential commercialization opportunities and could encourage pharmaceutical partners to develop regionally adaptable delivery systems over the next three to five years.
- Patient Centric Home Treatment: Pharmaceutical companies are developing injection formats suited to home administration. In August 2025, the FDA approved Leqembi IQLIK, a subcutaneous autoinjector presentation of lecanemab. SCHOTT Pharma's 5.5 milliliter syringe launch in October 2025 also supported home injection applications. These developments could increase demand for intuitive devices that reduce reliance on clinical administration.
Recent Developments in the Subcutaneous Drug Delivery Device Market
The subcutaneous drug delivery device market is advancing as pharmaceutical companies shift suitable therapies toward self administration and home based care. Recent approvals, wearable injector trials, and higher dose delivery systems are reshaping product development. Lucintel tracks these developments as manufacturers pursue broader therapeutic applications and commercial adoption.- Higher Dose Autoinjector Approval: In October 2024, the US Food and Drug Administration approved UCB’s 320 milligram BIMZELX presentation for single injection administration, replacing two successive 160 milligram injections. This development demonstrates how higher dose devices can simplify treatment regimens. Over the next three to five years, similar innovations could strengthen demand for advanced autoinjectors.
- Wearable Injector Clinical Advancement: In July 2025, BD announced the first pharmaceutical company sponsored combination product clinical trial using its Libertas wearable injector. The platform supports formulations up to 50 centipoise and delivery volumes of 2 to 10 milliliters. This milestone advances large volume biologic delivery and could expand opportunities for wearable systems as clinical programs progress.
- European Regulatory Expansion: In March 2025, Enable Injections received European Union medical device regulation CE Mark approval for its enFuse syringe transfer system. The approval supports commercialization across European markets for eligible subcutaneous drug delivery applications. Over the next three to five years, broader regulatory access could help manufacturers establish pharmaceutical partnerships and expand wearable injector adoption.
- at Home Alzheimer’s Treatment: In August 2025, the US Food and Drug Administration approved Leqembi IQLIK, a 360 milligram weekly subcutaneous injection for maintenance treatment of Alzheimer’s disease. Patients or caregivers can administer the medication using an autoinjector after at least 18 months of intravenous treatment. This approval could encourage development of additional self administered therapies.
- New Autoinjector Treatment Options: In April 2026, AstraZeneca received US approval for the Saphnelo Pen, enabling once weekly subcutaneous self administration for adults with systemic lupus erythematosus. The approval broadens delivery options for an established biologic therapy. Over the next three to five years, similar product conversions could increase demand for patient friendly devices.
Strategic Growth Opportunities in the Subcutaneous Drug Delivery Device Market
The subcutaneous drug delivery device market is creating new commercial opportunities as pharmaceutical companies develop biologics suited to self administration, larger injection volumes, and home based treatment. Recent regulatory approvals and device launches are expanding applications. Lucintel monitors these developments as manufacturers pursue differentiated products and pharmaceutical partnerships.- Large Volume Biologic Delivery: SCHOTT Pharma introduced a commercially available 5.5 milliliter prefillable glass syringe in October 2025, compatible with Ypsomed’s YpsoMate 5.5 autoinjector. This creates opportunities to supply complex biologics requiring higher injection volumes. Over the next three to five years, compatible syringes and delivery systems could attract pharmaceutical partnerships across immunology, oncology, and neurological treatments.
- Wearable Injector Commercialization: BD announced its first pharmaceutical company sponsored clinical trial using Libertas wearable injector technology in July 2025, supporting delivery volumes from 2 to 10 milliliters. Device developers can pursue partnerships for biologics unsuitable for conventional autoinjectors. Successful clinical development could create differentiated revenue streams through integrated devices, licensing agreements, and long term pharmaceutical supply contracts.
- Home Based Treatment Expansion: The US Food and Drug Administration approved Eisai’s Leqembi IQLIK in August 2025 as a 360 milligram subcutaneous autoinjector for eligible Alzheimer’s disease patients transitioning to maintenance treatment. This demonstrates commercial potential beyond traditional injectable therapies. Manufacturers could benefit from developing easy to use devices for chronic conditions, reducing dependence on clinic administered treatment where clinically appropriate.
- Integrated Safety System Development: SCHOTT Pharma and Nemera introduced a compatible 5.5 milliliter prefillable syringe and passive safety system in September 2026. This integrated design addresses compatibility and needle safety requirements for large volume injections. Device suppliers can expand revenue by offering pharmaceutical companies complete delivery solutions, potentially shortening integration timelines and differentiating products through usability and safety features.
- Geographic Market Expansion: Enable Injections announced Brazilian regulatory approval for its enFuse system in August 2025. This creates opportunities to extend wearable delivery platforms into additional healthcare markets through local regulatory approvals and pharmaceutical partnerships. Over the next three to five years, targeted regional expansion could diversify revenue, broaden patient access, and reduce dependence on established markets.
Subcutaneous Drug Delivery Device Market Drivers and Challenges
The subcutaneous drug delivery device market is shaped by rising demand for self administered therapies, advances in injection technology, expanding biologic treatments, and efforts to improve patient adherence. Regulatory requirements, device manufacturing costs, and product safety also influence commercialization. Lucintel monitors these factors as pharmaceutical companies develop more convenient delivery systems for chronic disease management and home based care.The factors responsible for driving the subcutaneous drug delivery device market include:
- Growing Demand for Self Administration: Chronic disease treatment increases demand for convenient injections. In July 2025, BD reported a clinical trial using its wearable injector, following more than 50 preclinical and clinical studies.
- Advances in Wearable Injection Technology: In March 2025, Enable Injections received European approval for its enFuse syringe transfer system, supporting wider adoption of wearable subcutaneous delivery.
- Expansion of Biologic Therapies: In April 2026, the FDA approved subcutaneous Saphnelo in prefilled syringe and autoinjector presentations, expanding delivery options for biologic treatment.
- Improved Patient Convenience: In July 2025, BD's Libertas injector supported delivery of biologics in 2 to 10 milliliter configurations, helping accommodate different dosing requirements.
- Regulatory Progress and Product Innovation: In August 2025, Enable Injections announced Brazilian approval for enFuse, opening another market for wearable subcutaneous delivery.
The challenges facing the subcutaneous drug delivery device market include:
- High Development Costs: Device design, testing, and drug compatibility assessments increase development expenses, potentially delaying commercialization.
- Regulatory and Safety Requirements: Combination products require rigorous validation of delivery accuracy, sterility, usability, and drug compatibility, increasing approval complexity.
- Patient Acceptance and Data Security: A 2026 stakeholder survey identified development costs, data security, and patient acceptance as barriers to connected device adoption.
List of Subcutaneous Drug Delivery Device Market Companies
Companies in the market compete on the basis of product quality offered. Major players in this market focus on expanding their manufacturing facilities, R&D investments, infrastructural development, and leverage integration opportunities across the value chain. Through these strategies subcutaneous drug delivery device market companies cater increasing demand, ensure competitive effectiveness, develop innovative products & technologies, reduce production costs, and expand their customer base.Some of the subcutaneous drug delivery device market companies profiled in this report include:
- Gerresheimer
- Medtronic
- Ypsomed
- Elcam Medical Group
- Novo Nordisk
Subcutaneous Drug Delivery Device Market by Segment
The study includes a forecast for the global subcutaneous drug delivery device market by product, distribution channel, and region.Product [Value ($B) from 2019 to 2035]:
- Prefilled Syringes
- Pen Injectors
- Auto-Injectors
- Wearable Injectors
- Needle-Free Injectors
Distribution Channel [Value ($B) from 2019 to 2035]:
- Hospital Pharmacies
- Retail Pharmacies
- Online Pharmacies
Region [Value ($B) from 2019 to 2035]:
- North America
- Europe
- Asia Pacific
- The Rest of the World
Country Wise Outlook for the Subcutaneous Drug Delivery Device Market
The subcutaneous drug delivery device market is evolving as pharmaceutical companies expand self administered therapies and develop systems for biologics requiring larger injection volumes. Advances in autoinjectors, wearable injectors, and prefilled pens are improving administration convenience. Lucintel tracks these developments alongside regulatory and manufacturing changes.- United States: In June 2024, the Food and Drug Administration issued draft guidance on essential drug delivery outputs, clarifying performance information expected for drug delivery devices and combination products. In March 2024, Mallinckrodt announced FDA approval of its single dose prefilled SelfJect injector for Acthar Gel. These developments strengthen regulatory clarity and support patient friendly treatment administration.
- China: In June 2025, Swiss device manufacturer Ypsomed opened its first Chinese production facility in Changzhou, a 15,000 square meter site designed to produce up to 100 million injection devices annually. The investment brings manufacturing closer to pharmaceutical customers and strengthens local supply capabilities for self injection systems.
- Germany: In October 2025, SCHOTT Pharma introduced a commercially available 5.5 milliliter prefillable glass syringe with an integrated needle, compatible with Ypsomed's large volume autoinjector. The launch expands packaging options for biologics and supports subcutaneous administration of larger doses outside clinical settings.
- India: In December 2025, Cipla launched Yurpeak, a tirzepatide injection for obesity and type 2 diabetes, in six strengths using Eli Lilly's KwikPen device. The launch expands access to injectable metabolic therapies and reinforces demand for convenient pen based drug delivery systems.
- Japan: In November 2025, Kyowa Kirin launched its LUMICEF 210 milligram subcutaneous injection pen after receiving approval in June 2025. The prefilled autoinjector simplifies administration and includes a locking needle cover, strengthening options for safer self injection among patients with inflammatory conditions.
Features of the Global Subcutaneous Drug Delivery Device Market
- Market Size Estimates: Subcutaneous drug delivery device market size estimation in terms of value ($B).
- Trend and Forecast Analysis: Market trends (2019 to 2026) and forecast (2027 to 2035) by various segments and regions.
- Segmentation Analysis: Subcutaneous drug delivery device market size by various segments, such as by product, distribution channel and region in terms of value ($B).
- Regional Analysis: Subcutaneous drug delivery device market breakdown by North America, Europe, Asia Pacific, and the Rest of the World.
- Growth Opportunities: Analysis of growth opportunities in different product, distribution channel and regions for the subcutaneous drug delivery device market.
- Strategic Analysis: This includes M&A, new product development, and competitive landscape of the subcutaneous drug delivery device market.- Analysis of competitive intensity of the industry based on Porter's Five Forces model.
This report answers the following 11 key questions:
Q.1. What are some of the most promising, high-growth opportunities for the subcutaneous drug delivery device market by product (prefilled syringes, pen injectors, auto-injectors, wearable injectors, and needle-free injectors), distribution channel (hospital pharmacies, retail pharmacies, and online pharmacies), and region (North America, Europe, Asia Pacific, and the Rest of the World)?Q.2. Which segments will grow at a faster pace and why?
Q.3. Which region will grow at a faster pace and why?
Q.4. What are the key factors affecting market dynamics? What are the key challenges and business risks in this market?
Q.5. What are the business risks and competitive threats in this market?
Q.6. What are the emerging trends in this market and the reasons behind them?
Q.7. What are some of the changing demands of customers in the market?
Q.8. What are the new developments in the market? Which companies are leading these developments?
Q.9. Who are the major players in this market? What strategic initiatives are key players pursuing for business growth?
Q.10. What are some of the competing products in this market and how big of a threat do they pose for loss of market share by material or product substitution?
Q.11. What M&A activity has occurred in the last 8 years, and what has its impact been on the industry?
This product will be delivered within 1-3 business days.
Table of Contents
Companies Mentioned
- Gerresheimer
- Medtronic
- Ypsomed
- Elcam Medical Group
- Novo Nordisk
Methodology
The analyst has been in the business of market research and management consulting since 2000 and has published over 600 market intelligence reports in various markets/applications and served over 1,000 clients worldwide. Each study is a culmination of four months of full-time effort performed by the analyst team. The analysts used the following sources for the creation and completion of this valuable report:
- In-depth interviews of the major players in the market
- Detailed secondary research from competitors’ financial statements and published data
- Extensive searches of published works, market, and database information pertaining to industry news, company press releases, and customer intentions
- A compilation of the experiences, judgments, and insights of professionals, who have analyzed and tracked the market over the years.
Extensive research and interviews are conducted in the supply chain of the market to estimate market share, market size, trends, drivers, challenges and forecasts.
Thus, the analyst compiles vast amounts of data from numerous sources, validates the integrity of that data, and performs a comprehensive analysis. The analyst then organizes the data, its findings, and insights into a concise report designed to support the strategic decision-making process.

LOADING...

